Skip to content
sellModerate

Catherine Moukheibir sold $1.1M of MLTX

director at MoonLake Immunotherapeutics. 23,500 shares at an average of $48.79, traded Jul 3, 2025, filed Jul 7, 2025.

Warning score
45
Value
$1.1M
23,500 shares
Holdings after
0
-100% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $1.1M at market
    +25
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +11.1%, 3m -81.8%, 6m -76.4%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

MLTXOct 9, 2026 · close 10.82
Since filing Jul 7, 2025: -77.2%SPY +27.1% · excess -104.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001213900-25-061752, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jul 3, 2025MOption exercise
Class A ordinary shares, par value $0.0001 per share
+23,500$0.00$023,500Jul 7, 2025
Jul 3, 2025SOpen-market sale
Class A ordinary shares, par value $0.0001 per share
-23,500$48.79$1.1M0Jul 7, 2025
Jul 3, 2025MOption exercise
Option to Buyderivative
-23,500$0.00$021,500Jul 7, 2025

Related signals

Other insiders at MoonLake Immunotherapeutics and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
0Weak
MLTXsell10b5-1
MoonLake Immunotherapeutics
Kristian Reich
Chief Scientific Officer
$22k
1,100 shares
-0%
28Weak
MLTXsell 210b5-1
MoonLake Immunotherapeutics
Kristian Reich
Chief Scientific Officer
$1.0M
52,448 shares
-2%
26Weak
MLTXsell 210b5-1
MoonLake Immunotherapeutics
Kristian Reich
Chief Scientific Officer
$878k
43,700 shares
-2%
17Weak
MLTXsell 210b5-1
MoonLake Immunotherapeutics
Kristian Reich
Chief Scientific Officer
$322k
16,105 shares
-1%
38Weak
MLTXsell 210b5-1
MoonLake Immunotherapeutics
da Silva Jorge Santos
Chief Executive Officer
$2.0M
102,225 shares
-4%
44Moderate
MLTXsell 310b5-1
MoonLake Immunotherapeutics
da Silva Jorge Santos
Chief Executive Officer
$957k
47,775 shares
-2%
40Moderate
MLTXsell 310b5-1
MoonLake Immunotherapeutics
Matthias Bodenstedt
Chief Financial Officer
$862k
39,120 shares
-3%
32Weak
MLTXsell 310b5-1
MoonLake Immunotherapeutics
Matthias Bodenstedt
Chief Financial Officer
$352k
17,876 shares
-2%
28Weak
MLTXsell 210b5-1
MoonLake Immunotherapeutics
Kristian Reich
Chief Scientific Officer
$2.9M
150,000 shares
-5%
15Weak
MLTXsell10b5-1
MoonLake Immunotherapeutics
Matthias Bodenstedt
Chief Financial Officer
$273k
13,653 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Catherine Moukheibir sold $1.1M of MLTX | InsiderTell